Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Chen, Bing ^a   Zeng, Zhao Chong ^a   Wang, Guo Min ^a   Zhang, Li ^a   Lin, Zong Ming ^a   Sun, Li An ^a   Zhu, Tong Yu ^a   Wu, Li Li ^a   Zhang, Jian Ying ^a   Ji, Yuan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; HEMOGLOBIN; MITOMYCIN C;

ADULT; AGE; ANOREXIA; ARTICLE; BLADDER SPASM; BLADDER TUMOR; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; KIDNEY PELVIS CARCINOMA; LEUKOCYTE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEPHROURETERECTOMY; OVERALL SURVIVAL; PROGNOSIS; RADIATION DOSE; RADIATION INDUCED EMESIS; SURVIVAL RATE; THROMBOCYTE; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; URETER CARCINOMA; AGED; DRUG EFFECT; FOLLOW UP; KAPLAN MEIER METHOD; KIDNEY PELVIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE; URETER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANOREXIA; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY PELVIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; URETER; URINARY BLADDER NEOPLASMS;

EID: 79960563810     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-297     Document Type: Article

References (17)

1. Genega EM, Porter CR. Urothelial neoplasms of the kidney and ureter. An epidemiology, pathologic and clinical review. Am J Clin Pathol 2002, 117(s1):s36-48.
2. Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU International 2006, 98:1181-86,. 10.1111/j.1464-410X.2006.06519.x, 17125475.
3. Tan LB, Chang LL, Cheng KI, Huang CH, Kwan AL. Transitional cell carcinomas of the renal pelvis and the ureter: comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population. BJU International 2008, 103:312-16.
4. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Critical Reviews in Oncol/Hematology 2003, 47:155-69.
5. Raman JD, Scherr DS. Management of patients with upper urinary tract transitional cell carcinoma. Nature Clinical Practice Urology 2007, 4:432-443.
6. Ozsahin M, Zouhair A, Villà S, et al. Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer 1999, 35:738-43. 10.1016/S0959-8049(99)00012-X, 10505034.
7. Maulard-Durdux C, Dufour B, Hennequin C, et al. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival?. J Urol 1996, 155:115-7.
8. Grigsby PW. Carcinoma of the urethra in women. Int J Radiat Oncol Biol Phys 1998, 41:535-541. 10.1016/S0360-3016(97)00773-6, 9635699.
9. Czito B, Zietman A, Kaufman D, et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol 2004, 172(4 Pt 1):1271-1275.
10. American Joint Committee on Cancer Renal pelvis and ureter. AJCC cancer staging manual 2002, 329-334. New York: Springer-Verlag, Greene FL, et al, 6, American Joint Committee on Cancer.
11. Trotti A, Byhardt R, Stetz J, et al. Common Toxicity Criteria (version 2.0): An improved reference for grading the acute effects of cancer treatment--Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000, 47:13-47. 10.1016/S0360-3016(99)00559-3, 10758303.
12. Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. European Urol 2009, 57:1072-9.
13. Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Raymond R. Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. Urology 1995, 46:796-800. 10.1016/S0090-4295(99)80346-X, 7502418.
14. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19:1592-9. 10.1093/annonc/mdn281, 18467316.
15. Bamias A, Deliveliotis C, Fountzilas G, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic cooperative oncology group. J Clin Oncol 2004, 22:2150-54. 10.1200/JCO.2004.09.043, 15169801.
16. Soga N, Arima K, Sugimura Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 2008, 15:800-803. 10.1111/j.1442-2042.2008.02114.x, 18651862.
17. Sakamoto N, Naito S, Kumazawa J, et al. Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. Int J Urology 2001, 8:212-16.